Drug intelligence / Profile preview

catalpol

Development stage
Phase 1
Lead developer
Suzhou Youseen New Drug R&D
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Oral, Intravenous, Intraperitoneal, Intragastric, Intracerebroventricular
01

Overview

Catalpol is a naturally occurring iridoid glycoside primarily isolated from the roots of Rehmannia glutinosa and other plants in the order Lamiales. It is classified as an iridoid monoterpene glucoside. Catalpol exhibits a broad spectrum of biological activities including neuroprotective, anti-inflammatory, antioxidant, hypoglycemic (anti-diabetic), anti-cancer, anti-apoptotic and pro-angiogenic effects. Mechanistically, its pharmacological actions are attributed to modulation of oxidative stress pathways (antioxidant), inhibition of inflammatory mediators (anti-inflammatory), reduction in apoptosis via mitochondrial pathways (anti-apoptotic), promotion of angiogenesis through upregulation of VEGF and erythropoietin expression in ischemic models (pro-angiogenic), and improvement in insulin resistance. Preclinical studies have demonstrated efficacy for conditions such as atherosclerosis by reducing plaque formation and vascular cell senescence; it also shows promise for neurologic disorders including depression, cognitive impairment/dementia/Alzheimer’s disease models, stroke recovery via neurogenesis/neuroplasticity promotion and Parkinson’s disease[2][3][9]. Toxicity studies indicate that catalpol has low toxicity with mild side effects observed at high doses or prolonged administration[3][7]. Despite promising preclinical data across multiple indications—including osteoporosis—well-controlled clinical trials are still needed to confirm its therapeutic potential.

Other names
catalpolCATAPOLCatalpol-RMcatalpinosideCatalnol
02

Targets

ACE (Angiotensin Converting Enzyme)IL1B (Interleukin-1 beta)NF-κBNLRP3 (Nod-like receptor family pyrin domain-containing protein 3)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on catalpol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on catalpol.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call